Back to Barclays plc Barclays plc

SMMT

19 quarters

Position history for Barclays plcBarclays plc's holdings in Summit Therapeutics Inc.

Yes. Barclays holds 123,360 shares of SMMT (Summit Therapeutics), worth $2.1M, as of its Q3 2026 13F filing. It reduced the position by 86,847 shares (-41.3%) from Q2 2026. Barclays has held SMMT since Q1 2022, across 19 quarterly 13F filings.

Current Value

$2.1M

Current Shares

123,360

Total Value Change

+$2.1M

Total Shares Change

+118,999

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q3
Latest
Decreased
123,360
-41.3%
$2.1M0.0%$16.91
0
2026-Q2
Increased
210,207
+328.1%
$3.1M0.0%$14.57
43
2026-Q1
Decreased
49,103
-85.5%
$930,9930.0%$18.96
0
2025-Q4
Decreased
338,390
-28.9%
$5.9M0.0%$17.49
0
2025-Q3
Increased
475,777
+51.6%
$9.8M0.0%$20.66
39
2025-Q2
Increased
313,824
+22.8%
$6.7M0.0%$21.28
33
2025-Q1
Decreased
255,612
-22.6%
$4.9M0.0%$19.29
0
2024-Q4
Increased
330,146
+32.0%
$5.9M0.0%$17.85
35
2024-Q3
Decreased
250,118
-35.4%
$5.5M0.0%$20.89
0
2024-Q2
Decreased
387,313
-1.5%
$3M0.0%$7.80
0
2024-Q1
Increased
393,312
+23.5%
$1.6M0.0%$4.14
31
2023-Q4
Increased
318,565
+115.2%
$831,4560.0%$2.61
40
2023-Q3
Increased
148,016
+206.6%
$276,7890.0%$1.87
38
2023-Q2
Decreased
48,272
-80.4%
$121,1630.0%$2.51
0
2023-Q1
Increased
246,464
+1678.4%
$431,3120.0%$1.63
39
2022-Q4
Increased
13,859
+563.4%
$58,9010.0%$4.25
23
2022-Q3
Increased
2,089
+85.2%
$2,0000.0%$1.19
12
2022-Q2
Decreased
1,128
-74.1%
$1,0000.0%$1.00
0
2022-Q1
New
4,361
-
$11,0000.0%$2.45
26

Other major holders of SMMT: Baker Bros. Advisors LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used